Zusammenfassung
Das Blut erfüllt Transport-, Gerinnungs- und Abwehrfunktionen, vermittelt durch Blutzellen und -plasma. Die zellulären Bestandteile (Erythro-, Leuko- und Thrombozyten) werden im Knochenmark aus hämatopoetischen Stammzellen gebildet; Syntheseort der plasmatischen Gerinnung ist die Leber. Blutzellen und Gerinnungsfaktoren unterliegen einem ständigen Umsatz im Körper. Störungen dieses Systems beeinträchtigen die o. g. Funktionen und wirken sich letztlich auf den Gesamtorganismus aus.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Barbui T et al: Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2004. 89(2): p. 215‑32
Bene MC et al: Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia, 1995. 9(10): p. 1783–6
Bennett JM et al: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol, 1976. 33(4): p. 451‑8
Berufskrankheitenverordnung (BKV), Anlage 1. BGBl, 2009. I(30): p. 1273
Binet JL et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 1981. 48(1): p. 198–206
Brenner H, Gondos A, Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood, 2008. 111(5): p. 2521–6
Burchert A et al: Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia. J Clin Oncol, 2010
Buske C et al: The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated frontline with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood, 2006. 108(5): p. 1504–8
Carbone PP et al: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res, 1971. 31(11): p. 1860–1
Durie BG, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 1975. 36(3): p. 842–54
Faderl S et al: Adult acute lymphoblastic leukemia: concepts and strategies. Cancer, 2010
Gokbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Semin Hematol, 2009. 46(1): p. 64–75
Greipp PR et al: International staging system for multiple myeloma. J Clin Oncol, 2005. 23(15): p. 3412–20
Griesshammer M: Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost, 2006. 32(4 Pt 2): p. 372–80
Haferlach T et al: Genetic classification of acute myeloid leukemia (AML). Ann Hematol, 2004. 83 Suppl 1: p. S97–100
Harris NL et al: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol, 1999. 10(12): p. 1419–32
Hasford J et al: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst, 1998. 90(11): p. 850–8
Henry J, Brüning T: Erkrankungen des Blutes, des blutbildenden und lymphatischen Systems durch Benzol. IPA-Journal, Institut für Prävention und Arbeitsmedizin der Deutschen gesetzlichen Unfallversicherung, Ruhr-Universität Bochum, 2009. 01/09: p. 6–10
Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost, 2006. 32(4 Pt 2): p. 362–71
Levine RL, Gilliland DG: Myeloproliferative disorders. Blood, 2008. 112(6): p. 2190–8
Malcovati L, Nimer SD: Myelodysplastic syndromes: diagnosis and staging. Cancer Control, 2008. 15 Suppl: p. 4–13
Malcovati L et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol, 2007. 25(23): p. 3503–10
Marsh JC et al: Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol, 2009. 147(1): p. 43–70
Oldenburg J, Barthels M: Angeborene Koagulopathien am Beispiel der Hämophilie A und B, Hemmkörperhämophilie. Hamostaseologie, 2008. 28(5): p. 335–47
Savage DG, Antman KH: Imatinib mesylate--a new oral targeted therapy. N Engl J Med, 2002. 346(9): p. 683–93
Sokal JE et al: Prognostic discrimination in »good-risk» chronic granulocytic leukemia. Blood, 1984. 63(4): p. 789–99
Solal-Celigny P et al: Follicular lymphoma international prognostic index. Blood, 2004. 104(5): p. 1258–65
Sweetenham JW: Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Program, 2005: p. 252–9
Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 2008. 22(1): p. 14–22
Vardiman JW et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 2009. 114(5): p. 937–51
White GC, 2nd, et al: Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost, 2001. 85(3): p. 560
Wolanskyj AP et al: Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc, 2006. 81(2): p. 159–66
Weiterführende Literatur
Deutsche Rentenversicherung: Leitlinien für die sozialmedizinische Begutachtung – Rehabilitationsbedürftigkeit bei onkologischen Erkrankungen. Deutsche Rentenversicherung Bund (Hrsg.). Berlin, Januar 2011. www.deutsche-rentenversicherung.de
Deutsche Rentenversicherung: Leitlinien für die sozialmedizinische Begutachtung – Sozialmedizinische Beurteilung bei Mammakarzinom. Deutsche Rentenversicherung Bund (Hrsg.). Berlin, Januar 2011. www.deutsche-rentenversicherung.de
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
König, V. (2011). Hämatologische und immunologische Krankheiten. In: Sozialmedizinische Begutachtung für die gesetzliche Rentenversicherung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-10251-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-10251-6_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-10249-3
Online ISBN: 978-3-642-10251-6
eBook Packages: Medicine (German Language)